Related Experiment Video

Updated: Jun 8, 2025

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

11.3K

Avoiding arrythmias by personalizing the dialysate concentration: a case for precision medicine in patients on

T Alp Ikizler1, Tilman B Drueke2, Jürgen Floege3

  • 1Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Kidney International
|November 3, 2024
PubMed

Insights

For hemodialysis patients with hyperkalemia, a higher dialysate potassium level (3 mEq/l) and sodium zirconium cyclosilicate on non-dialysis days reduced atrial fibrillation frequency. This pilot study suggests a personalized approach may improve cardiovascular outcomes.

Area of Science:

  • Nephrology
  • Cardiology
  • Clinical Trials

Background:

  • Cardiac arrhythmias, particularly atrial fibrillation, are prevalent in patients undergoing maintenance hemodialysis.
  • Hyperkalemia is a common complication in this patient population, increasing cardiovascular risk.

Purpose of the Study:

  • To evaluate the efficacy of a personalized potassium management strategy in reducing atrial fibrillation frequency in hemodialysis patients with hyperkalemia.

Main Methods:

  • A pilot study involving hemodialysis patients with hyperkalemia (serum potassium 5.10-6.50 mmol/l).
  • Patients received either a 3 mEq/l dialysate potassium concentration plus sodium zirconium cyclosilicate on dialysis-free days, or a 2 mEq/l dialysate potassium concentration.
  • The study duration was 8 weeks.

Main Results:

  • The group using a 3 mEq/l dialysate potassium concentration with sodium zirconium cyclosilicate showed a lower frequency of atrial fibrillation compared to the 2 mEq/l group.
  • This personalized approach was associated with a reduction in atrial fibrillation over the 8-week study period.

Conclusions:

  • A personalized approach to potassium management, involving adjusted dialysate concentration and oral potassium binders, may decrease atrial fibrillation in hemodialysis patients with hyperkalemia.
  • Further large-scale prospective trials are warranted to confirm these findings and assess long-term cardiovascular outcomes.

More Related Videos

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

2.5K
Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging13:21

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging

Published on: July 21, 2011

14.9K

Related Concept Videos

Dialysis01:15

Dialysis

Dialysis is a diffusion-based purification process that separates analyte molecules from a complex matrix. This is accomplished by allowing molecules in the solution to pass through a semipermeable membrane into a liquid on the other side. The membrane is usually made of cellulose acetate or cellulose nitrate, and the second liquid must be miscible with the solution. Ions (e.g., chloride or sodium) or organic molecules (e.g., glucose) can pass through the membrane pores, which generally have...
602
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
345
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
463
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
525
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
45